The General Meeting of Scandinavian Real Heart AB (publ) ("Realheart" or the "Company") has resolved to carry out a rights issue of a maximum of 4,998,704 shares with preferential rights for existing shareholders (the "Rights Issue"). The subscription period is planned to run from 13 January 2026 up to and including 27 January 2026. Upon full subscription in the Rights Issue, the Company will receive approximately SEK 70 million before issue costs. The Rights Issue is covered to approximately 70 percent by guarantee commitments and subscription commitments from existing shareholders, the Board of Directors and senior executives.

Summary

• Upon full subscription in the Rights Issue, Realheart will receive approximately SEK 70 million before issue costs.
• The Rights Issue is approximately 70 percent covered by guarantee commitments.
• The subscription period for the Rights Issue is planned to run from 13 January 2026 up to and including 27 January 2026.
• Shareholders who, on the record date of 9 January 2026, were registered as shareholders in accordance with the share register maintained by Euroclear Sweden AB ("Euroclear Sweden") on behalf of Scandinavian Real Heart AB have preferential rights to subscribe for new shares in relation to their existing shareholdings in the Company on the record date. Holding one (1) share as of the record date entitles the holder to one (1) subscription right, whereby one (1) subscription right entitles the holder to subscribe for one (1) share.
• The subscription price is SEK 14.00 per new share.

Reasons for the issue and use of the proceeds

Scandinavian Real Heart AB carries out the Rights Issue of approximately SEK 70 million in order to secure continued financing of the company's development work with Realheart® TAH – a totally artificial heart designed to mimic the structure and function of the human heart. The product is intended to become a permanent solution for patients with severe heart failure. Previous study results support that Realheart TAH has good potential to replace the human heart in the future.

Of the approximately 22 million patients suffering from heart failure in the EU and the US, the company estimates that a patient base of approximately 160 thousand patients suffering from advanced (NYHA class IV), biventricular heart failure includes the target group for TAH treatment. Furthermore, this is estimated to translate into an annual number of patients in need of TAH treatment to about 25 thousand, and is expected to follow the same increase as heart failure in general to about 35 thousand by 2030. The average market price for one TAH is $220 kUSD, which means a market potential of $34 billion USD. The US and EU are the largest markets, of which Germany is the largest European market and therefore of great interest to the company. A collaboration with a German hospital has been initiated for future clinical trials.

In 2025, the company has deepened its collaboration with Sahlgrenska University Hospital in Gothenburg, where surgical methodology and processes have been further developed based on experiences from previous animal studies. The studies are led by cardiac surgeon Professor Göran Dellgren together with a clinical team with extensive experience in heart transplants.

The aim is to first optimize the surgical methodology, then conduct survival studies to gather regulatory data, and finally apply to initiate clinical trials.

In 2025, the company has also increased its focus on product development. The company has produced a number of units of TAH with improved quality and simplified manufacturing processes compared to before.

The company will continue to develop production processes and product quality, both through internal initiatives and in close collaboration with carefully selected partners. As part of this work, there will be a move to more appropriate premises in 2026.

The units of TAH that the company manufactures will be used on an ongoing basis in both endurance tests that run continuously for up to six months and animal studies as well as blood tests. Endurance tests of the membrane, the most critical component has reached more than 20 months in ongoing tests.

To enable the transition to clinical studies, further design improvements to the product are required, which must be validated through endurance tests, animal studies and blood tests. This work has already begun and will continue in 2026. Several studies have been conducted with previous versions compared to market-leading competitors that show superior results in blood tests and in patient simulator studies (cardiovascular simulator, so-called hybrid simulator).

At full subscription, the proceeds (after issue costs of approximately SEK 300,000) are planned to be used as follows:

TAH unit – 60%

• Production of TAH units
• Product development
• Product quality
• Production Process
• Suitable premises

Preclinical studies – 28%

• Endurance tests
• Animal studies
• Blood tests

Regulatory work – 2%

Company costs – 10%

The liquidity is estimated to be sufficient to finance the working capital requirement for 12 months.

Terms and conditions for the Rights Issue

• Upon full subscription in the Rights Issue, the Company will receive issue proceeds of approximately SEK 70 million before issue costs.
• Shareholders who, on the record date of 9 January 2026, were registered as shareholders in accordance with the share register maintained by Euroclear Sweden AB ("Euroclear Sweden") on behalf of Scandinavian Real Heart AB have preferential rights to subscribe for new shares in relation to their existing shareholdings in the Company on the record date. Holding one (1) share as of the record date entitles the holder to one (1) subscription right, whereby one (1) subscription right entitles the holder to subscribe for one (1) share.
• The subscription price is SEK 14.00 per new share. No commission is charged.
• The Rights Issue entails an issue of a maximum of 4,998,704 shares.

Change in number of shares and share capital and dilution

• Upon full subscription in the Rights Issue, the number of shares in the Company will increase by a maximum of 4,998,704 shares, from 4,998,704 shares to a maximum of 9,997,408 shares.
• The share capital will increase by a maximum of SEK 25,043,507.040, from SEK 25,043,507.040 to a maximum of SEK 50,087,014.080, calculated based on a quota value of SEK 5.01 per share.
• The dilution effect amounts to a maximum of 50 percent of the total number of shares and votes in the Company.

The Information document

In connection with the Rights Issue, the Company has prepared an information document (the "Information Document") in accordance with Article 1.4 db of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, as amended (the "Prospectus Regulation"). The information document has been prepared in accordance with the requirements of Annex IX to the Prospectus Regulation.

Full terms and conditions of the issue can be found in the Information Document.

Realheart today announces that the Information Document has been registered with the Swedish Financial Supervisory Authority and is available on the Company's website, https://realheart.se/preferential-rights-issue-realheart/. Application forms for subscription without preferential rights will be available on Nordic Issuing AB's website.

Subscription commitments and guarantee commitments

The company has received subscription commitments from existing shareholders, the Board of Directors and senior executives of approximately SEK 25.6 million. Which in total corresponds to approximately 36.5% of the rights issue. Furthermore, the Company has received guarantee commitments from existing shareholders of approximately SEK 23.4 million. Which in total corresponds to approximately 33.5% of the rights issue. In total, the rights issue is thus covered to approximately 70% of subscription and guarantee commitments. The guarantee commitments only cover the part of the issue that is not covered by subscription commitments and subscription with subscription rights, up to a total coverage ratio of 70 percent of the issue amount. If the issue is subscribed to 70 percent or more without the need to use the guarantee, the guarantee obligations lapse. No compensation will be paid for subscription and guarantee commitments. Neither the subscription nor the guarantee commitments are secured by bank guarantees, escrow funds, pledging or similar arrangements.

Preliminary timetable for the Rights Issue

Issuing Institute

Nordic Issuing AB is the issuing agent in connection with the Rights Issue.

For further information, please contact:

Ina Laura Perkins, VD

Phone: +46(0)70 406 49 21

E-post: inalaura.perkins@realheart.se

About Scandinavian Real Heart AB

Scandinavian Real Heart AB is developing a complete artificial heart (Total Artificial Heart – TAH) for implantation in patients with life-threatening heart failure. The company's TAH has a patented design that includes a replica of the natural human heart. Realheart TAH incorporates a four-chamber® system (two atria, two chambers) which provides the opportunity to generate a physiologically adapted blood flow that mimics the body's natural circulation. A concept that is unique in the world of medical devices.

Important information

The publication, publication or distribution of this press release may be subject to restrictions by law in certain jurisdictions and persons in the jurisdictions in which this press release has been published or distributed should inform themselves of and comply with such legal restrictions. The recipient of this press release is responsible for using this press release and the information contained herein in accordance with applicable regulations in their respective jurisdictions. This press release does not constitute an offer, or a solicitation of any offer, to acquire or subscribe for any securities in Realheart in any jurisdiction, neither from Realheart nor from anyone else.

This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. No prospectus will be prepared in connection with the Rights Issue. The Company will prepare and publish an information document in the form prescribed in Annex IX to the Prospectus Regulation.

This press release does not identify or purport to identify risks (direct or indirect) that may be attributable to an investment in the Company. The information in this press release is only to describe the background to the Rights Issue and does not claim to be complete or exhaustive. No assurance should be made in relation to the information in this press release regarding its accuracy or completeness.

This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration, or without the application of an exemption from registration, under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration, an exemption from, or in a transaction not subject to the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States, or to make a public offer of such securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United States, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea or any other jurisdiction where such announcement, publication or distribution of this information would be contrary to applicable regulations or where such action is subject to legal restrictions or would require additional registration or other measures than what follows from Swedish law. Actions in violation of this instruction may constitute a violation of applicable securities legislation.

Forward-Looking Statements

This press release may contain forward-looking statements that reflect the Company's intentions, beliefs or current expectations and goals for the Company's future operations, financial condition, liquidity, performance, prospects, expected growth, strategies and opportunities, and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and can be identified by words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "may" or, in each case, their negative, or similar, expressions. The forward-looking statements in this press release are based on various assumptions, many of which are based on additional assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it cannot give any assurance that they will occur or prove to be accurate. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, actual results or results could differ materially from those expressed in the forward-looking statements, which are the result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this press release by such forward-looking statements. The Company does not warrant that the assumptions behind the forward-looking statements in this press release are free from errors and does not accept any responsibility for the future accuracy of the opinions expressed in this press release or any obligation to update or revise the statements in this press release to reflect subsequent events. The information, opinions and forward-looking statements contained in this press release relate only to the situation as of the date hereof and are subject to change without notice. The Company undertakes no obligation to review, update, confirm or publish any revisions to any forward-looking statements to reflect events that arise or circumstances that arise in relation to the content of this press release.

Information for distributors

In order to comply with the product governance requirements set out in: (a) Directive 2014/65/EU of the European Parliament and of the Council on markets in financial instruments, as amended, ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593, supplementing MiFID II; and (c) local implementing measures (collectively, the "MiFID II Product Governance Requirements"), and disclaiming any and all liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the shares offered have been subject to a product approval process, which has determined that such securities are: (i) suitable for an end target market of retail investors, and investors who meet the criteria of professional clients and eligible counterparties, as defined in MiFID II; and (ii) suitable for distribution through all distribution channels permitted under MiFID II (the "Target Market Assessment"). Notwithstanding the Target Market Assessment, distributors should note that: the price of the Company's shares may decrease and investors may lose all or part of their investment, that the Company's shares are not accompanied by any guarantee of return or capital protection, and that an investment in the Company's shares is only suitable for investors who are not in need of guaranteed returns or capital protection and who (alone or with the assistance of appropriate financial or other advisors) are capable of evaluating the benefits and risks of such investment and which has sufficient resources to bear the losses that such investment may result in. The target market assessment is without prejudice to other requirements regarding contractual, legal or regulatory sales restrictions due to the Rights Issue. For the avoidance of doubt, the Target Market Assessment does not constitute (a) an appropriateness or suitability assessment within the meaning of MiFID II or (b) a recommendation to any investor or group of investors to invest in, acquire, or take any other action in respect of the Company's shares. Each distributor is responsible for conducting its own Target Market Assessment in respect of the Company's shares and for deciding on appropriate distribution channels.

The Board of Directors propose that the General Meeting resolves on issuance of new shares, with preferential rights for the shareholders in accordance with below.

Reasons for the Offering and Use of Proceeds

Scandinavian Real Heart AB is conducting the Rights Issue of approximately SEK 70 million to secure continued financing of the Company’s development work on Realheart® TAH – a total artificial heart designed to mimic the structure and function of the human heart. The product is intended to become a permanent solution for patients suffering from severe heart failure. Previous study results support that Realheart TAH has strong potential to replace the human heart in the future.

Of the approximately 22 million patients suffering from heart failure in the EU and the US, the Company estimates that a patient population of around 160,000 with advanced (NYHA Class IV) biventricular heart failure represents the target group for TAH treatment. Furthermore, this translates into an annual number of patients requiring TAH treatment of approximately 25,000, expected to increase in line with overall heart failure prevalence to around 35,000 by 2030. The average market price for a TAH is USD 220,000, corresponding to a market potential of USD 34 billion. The US and EU are the largest markets, with Germany being the largest European market and therefore of significant interest to the Company. A collaboration with a German hospital has been initiated in preparation for future clinical trials.

In 2025, the Company deepened its collaboration with Sahlgrenska University Hospital in Gothenburg, where surgical methodology and processes have been further developed based on experience from previous animal studies. The studies are led by cardiac surgeon Professor Göran Dellgren together with a clinical team with extensive experience in heart transplantation. The objective is first to optimize surgical methodology, then conduct survival studies to compile regulatory documentation, and finally apply to initiate clinical trials.

During 2025, the Company also increased its focus on product development. The Company has produced several TAH units with improved quality and simplified manufacturing processes compared to previous versions. The Company will continue to develop production processes and product quality, both through internal initiatives and in close collaboration with carefully selected partners. As part of this work, a move to more suitable facilities will take place in 2026. The TAH units manufactured by the Company will continuously be used in endurance tests running for up to six months, as well as in animal studies and blood tests. Endurance tests of the membrane, the most critical component, have exceeded 18 months in ongoing tests. To enable the transition to clinical studies, further design improvements of the product are required, which must be validated through endurance tests, animal studies, and blood tests. This work has already begun and will continue during 2026. The company is not communicating any guidance or forecast regarding the anticipated date for the first-in-human implant. Several studies have been conducted with previous versions compared to the market-leading competitor, showing superior results in blood tests and patient simulator studies (cardiovascular simulator, so-called hybrid simulator).

If fully subscribed, the net proceeds (after estimated transaction costs of approximately SEK 300,000) are intended to be allocated as follows:

TAH Unit – 60%

• Production of TAH units
• Product development
• Product quality
• Manufacturing process
• Suitable facilities

Preclinical Studies – 28%

• Endurance tests
• Animal studies
• Blood tests

Regulatory Work – 2%

Corporate Costs – 10%

The proceeds are expected to be sufficient to finance working capital requirements for approximately 12 months.

Subscription and Guarantee Commitments

The Company has received subscription undertakings from existing shareholders, the Board of Directors, and senior management amounting to approximately SEK 25.6 million, corresponding to about 36.5% of the rights issue. In addition, the Company has obtained guarantee commitments from existing shareholders totalling approximately SEK 23.4 million, which represents about 33.5% of the rights issue. In aggregate, the rights issue is thus covered to approximately 70% by subscription and guarantee commitments. The guarantee commitments only cover the portion of the issue not subscribed for through subscription undertakings and subscriptions based on subscription rights, up to a total coverage level of 70% of the issue amount. If the rights issue is subscribed to 70% or more without the need to utilize the guarantees, the guarantee commitments will lapse. No compensation will be paid for the subscription and guarantee commitments.

Number of shares and share capital increase

The issue comprises no more than 4 998 704 new shares

The Company’s share capital may be increased by no more than SEK 25 043 507.040. The share capital increases have been calculated based on a quotient value of SEK 5.01 per share.

Right to subscribe for shares

The shareholders of the Company shall have preferential rights to subscribe for shares. For each share held on the record date, the shareholder receives one subscription right, whereby one subscription right entitles to subscribe for one share. The record date for determining which shareholders shall be entitled to subscribe for shares on a preferential basis shall be 1 December 2025.

In case not all shares have been subscribed for, the Board of Directors shall decide that allotment of shares subscribed for without subscription rights shall take place up to the maximum amount of the issue, whereby the Board of Directors primarily will allot shares to those who also subscribed for shares based on subscription rights, and in the event of over subscription, pro rata to their subscription based on subscription rights. Secondly, the Board of Directors will allot shares to those who subscribed for shares without subscription rights, and if full allotment cannot be made, the board shall have the right to freely decide on allotment.

Subscription price of shares

The subscription price is SEK 14 per share.

The share premium shall be transferred to the unrestricted premium reserve.

Subscription and payments of shares

Subscription for shares based on subscription rights shall be made through payment in cash during the period from 3 December 2025 until, and including 17 December 2025. The Board of Directors shall be entitled to extend the subscription period.

Subscription without subscription rights shall be made through notice on special application form during the period from 3 December 2025 until and including 17 December 2025. The Board of Directors shall be entitled to extend the subscription period. Payment for shares shall be made at the latest three business days following the date of the dispatch of a contract note to the subscriber, specifying allocation of shares, or such later date as the Board of Directors may decide.

Trading with subscription rights is expected to take place during the period from 3 December 2025 until, and including 12 December 2025.

Right to dividends of new shares

The new shares shall entitle to dividends as from the first record date for dividends following registration of the new shares with the Swedish Companies Registration Office.

Miscellaneous

It was furthermore proposed that the Board of Directors, the CEO, or the person ap-pointed by the Board of Directors or the CEO, shall be authorized to make such minor amendments to the resolution as may be required in connection with the registration or execution of the resolution with the Swedish Companies Registration Office or Euroclear Sweden AB.

_____________

The Board of Directors in Scandinavian Real Heart AB